VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 3, 2013) -RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB:REPCF)(CNSX:RP) reports that its Chief Scientific Officer, Dr. Kevin McElwee, will be presenting at the 7th World Congress for Hair Research in Edinburg, Scotland from May 4-6^th , 2013. Dr. McElwee will be discussing 12-month safety results from RepliCel's Phase I clinical trial using RCH-01 as a potential solution for androgenetic alopecia.

The World Congress for Hair Research meeting brings together hair research societies from all over the world - comprised of physicians, dermatologists and scientists working in academia - devoted to unraveling the causes, and effective treatments, for hair related disorders. As the field of clinical hair research continues to expand, the exchange of ideas, research findings, and information from recognized industry leaders has proven to be invaluable in outlining future strategies. For more information please visit [ www.hair2013.org ].

About RepliCel Life Sciences

The Company is developing two autologous cell therapies. The first is a cellular treatment for androgenetic alopecia (pattern baldness) named RepliCel Hair-01 (RCH-01). The second is a cell therapy for the treatment of chronic tendon injuries named RepliCel Tendon-01 (RCT-01). Both treatments are based on RepliCel's innovative technology which utilizes cells isolated from a patient's own healthy hair follicles to address specific cellular deficits. Phase II clinical trials, for both technologies, are planned for the later part of 2013.

Notice Regarding Forward-Looking Statements

This press release contains projections and forward-looking statements, as that term is defined under applicable securities laws. Statements in this press release, which are not purely historical, are forward-looking statements that relate to the approval and commercialization of the Company's hair restoration process, the Company's development of its Achilles tendon technology, the expected commencement of the Company's Phase II clinical trial for its tendon technology, that the RepliCel tendon technology will provide therapeutic benefit, in terms of pain and function, for tendonosis, that the new hair follicle derived from fibroblast isolated from NBDS cells will provide improved cell population in the tendon to further enhance tendon treatment, and the expected commencement of the Company's Phase II clinical trial for its hair restoration technology. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: negative results from the Company's clinical trials; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; risks and uncertainties associated with the Company's ability to raise additional capital; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2012 and other periodic reports filed from time-to-time with the Securities and Exchange Commission on Edgar at [ www.sec.gov ] and with the British Columbia Securities Commission on Sedar at [ www.sedar.com ].

Contributing Sources

---

Market Wire